Edwin Rock
Known title: Chief Medical OfficerCIK: 0001945417
Edwin Rock's purchase track record
How the stock did after each of Edwin Rock's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
Purchases measured
4
of 4 since November 14, 2022
Stock higher 6 months later
50%
3 months: 50%
Median 6-month return
+23.9%
3 months: +11.2%
Beat the S&P 500
50%
median +14.4% vs. index
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 6/20/2024 | CBIO | $79K | -32.0% | -16.0% | +7.2% |
| 9/21/2023 | CBIO | $90K | +54.4% | +108.7% | +21.1% |
| 12/22/2022 | CBIO | $248K | -32.4% | -8.8% | +14.6% |
| 11/14/2022 | CBIO | $309K | +184.4% | +56.5% | +4.5% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| CBIO | ▲ Buy | Open Market | 115,000 | $31K | 6/21/2024 | View on chart |
| CBIO | ▲ Buy | Open Market | 190,000 | $48K | 6/20/2024 | View on chart |
| CBIO | ▲ Buy | Open Market | 30,403 | $42K | 9/22/2023 | View on chart |
| CBIO | ▲ Buy | Open Market | 35,000 | $48K | 9/21/2023 | View on chart |
| CBIO | ▲ Buy | Open Market | 110,000 | $248K | 12/22/2022 | View on chart |
| CBIO | ▲ Buy | Open Market | 100,000 | $166K | 11/15/2022 | View on chart |
| CBIO | ▲ Buy | Open Market | 100,000 | $143K | 11/14/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
CBIO Announces New Clinical Trial Milestones for CR-001
Crescent Biopharma said it is enrolling patients in the standard‑of‑care chemotherapy arms of its global Phase 1/2 ASCEND trial for CR‑001, a PD‑1 × VEGF bispecific antibody. The company also began additional antibody‑drug‑conjugate combination studies with CR‑001. These steps indicate progress in the drug’s development and broaden its potential clinical applications.
CBIO Announces New Clinical Trial Milestones for CR-001. Crescent Biopharma said it is enrolling patients in the standard‑of‑care chemotherapy arms of its global Phase 1/2 ASCEND trial for CR‑001, a PD‑1 × VEGF bispecific antibody. The company also began additional antibody‑drug‑conjugate combination studies with CR‑001. These steps indicate progress in the drug’s development and broaden its potential clinical applications.